CHUV

Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

Retrieved on: 
Venerdì, Maggio 24, 2024
Patient, European Renal Association, Kidney, Risk, Dialysis, Nephritis, Recurrence, Disease, Head, Nephrology, APLS, Congress, VALIANT, Inflammation, Proteinuria, CHUV, ERA, Failure, Pharmaceutical industry

These data were presented during a late-breaking oral presentation at the European Renal Association (ERA) Congress taking place May 23-26 in Stockholm, Sweden.

Key Points: 
  • These data were presented during a late-breaking oral presentation at the European Renal Association (ERA) Congress taking place May 23-26 in Stockholm, Sweden.
  • “Post-transplant C3G and IC-MPGN patients are likely to experience disease recurrence, putting them at risk of needing another kidney transplant or dialysis.
  • Additionally, treatment with pegcetacoplan resulted in sustained improvements in key measures of disease including proteinuria and continued stabilization of kidney function.
  • “These findings underscore our conviction in pegcetacoplan’s potential to address these rare, severe, and life-threatening conditions in both native and post-transplant kidneys."

THERYQ and Gustave Roussy have been selected as part of the "i-Démo" France 2030 call for projects, operated on behalf of the French government by Bpifrance, for the "FLASHDEEP" project, for an amount of 38 million euros

Retrieved on: 
Venerdì, Febbraio 2, 2024
CERN, Radiation therapy, Neoplasm, Research, Teaching hospital, DGE, Gustave Roussy, CHUV, Patient, FLASH, Radiation, Physician, Electron, Cancer, CE, Radiobiology, Pharmaceutical industry

FLASHDEEP will be the world's first FLASH radiotherapy device using very high-energy electrons (VHEE; > 100 MeV).

Key Points: 
  • FLASHDEEP will be the world's first FLASH radiotherapy device using very high-energy electrons (VHEE; > 100 MeV).
  • The particle acceleration technology developed by THERYQ stems from research initiated by the European Organization for Nuclear Research (CERN) and the University Hospital of Lausanne (CHUV).
  • The first clinical FLASHDEEP device will be installed in France, at Gustave Roussy, late 2026, to conduct clinical trials with eligible patients.
  • Ultimately, it will lead to the revival of a French radiotherapy industrial sector, a field that has been neglected since the late 1980s.

Biospectal OptiBP Receives First-Ever CE Mark for a Smartphone Blood Pressure Monitoring App

Retrieved on: 
Mercoledì, Dicembre 6, 2023
Apps, Applications, Mobile, Wireless, Technology, Medical Devices, Software, Audio, Video, Other Health, General Health, Health, Data Management, World Health Organization, Hypertension, Research, Android, Electronics, MDR, Smartphone, Patient, European, Algorithm, CE, Google Play, Anesthesiology, System, Lausanne University Hospital, Partnership, CHUV, Certification, Telehealth, Professor, Blood pressure, Medical device, Pharmaceutical industry, Microtechnology

Biospectal , the remote monitoring and biosensing software company, today announced it has received European CE MDR Class IIa medical device certification for its optical fingertip blood pressure monitoring app, OptiBP™ — the first and only software app worldwide to receive the CE mark for measuring blood pressure on a smartphone.

Key Points: 
  • Biospectal , the remote monitoring and biosensing software company, today announced it has received European CE MDR Class IIa medical device certification for its optical fingertip blood pressure monitoring app, OptiBP™ — the first and only software app worldwide to receive the CE mark for measuring blood pressure on a smartphone.
  • The Biospectal OptiBP app uses the built-in camera lens on a smartphone to record an individual’s blood flow easily via their fingertip.
  • OptiBP records fingertip blood flow optically and transforms that information into a pulse wave that it analyzes to estimate blood pressure.
  • By allowing blood pressure to be measured at the ‘point of patient,’ OptiBP enables more frequent, trackable and shareable information to support better blood pressure management and better life outcomes.

Masimo W1™ Medical Watch Receives FDA 510(k) Clearance for Over-the-Counter and Prescription Use

Retrieved on: 
Venerdì, Novembre 17, 2023
Pharmaceutical, Health, FDA, Medical Devices, Consumer Electronics, Health Technology, Wearables, Mobile Technology, Technology, ECG, Empowerment, COPD, MASI, Virtual Health Library, Pulse, Patient, Multimedia, Algorithm, Heart rate, Anesthesiology, CHUV, Hospital, PR, Oxygen saturation (medicine), CHF, OTC, Physiology, Medical imaging, Masimo

Masimo (NASDAQ: MASI) today announced that the Masimo W1™ medical watch has received FDA 510(k) clearance for over-the-counter (OTC) and prescription use (Rx).

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that the Masimo W1™ medical watch has received FDA 510(k) clearance for over-the-counter (OTC) and prescription use (Rx).
  • The FDA clearance expands the indications for the Masimo W1 in the U.S. as a medical device for use by adults in hospitals, clinics, long-term care facilities, and in the home.
  • The continuous data from the Masimo MW-1 module is displayed in real-time on the Masimo W1 watch touchscreen in an easy-to-interpret format.
  • The Masimo W1 and the integrated Masimo MW-1 Module are indicated for adults in hospitals, clinics, long-term care facilities, and homes.

RaySearch Laboratories: Interim report January 1 - September 30, 2023

Retrieved on: 
Venerdì, Novembre 17, 2023
Paul Scherrer Institute, CFO, Mass, Cyberknife, CET, University Medical Center Groningen, RaySearch Laboratories, Lausanne University Hospital, University, Partnership, CHUV, Pharmaceutical industry, Nursing, Flour

RaySearch and MedAustron expand their partnership through a new strategic research agreement.

Key Points: 
  • RaySearch and MedAustron expand their partnership through a new strategic research agreement.
  • RaySearch's business partner IBA has placed an order for RayStation and RayCare for installation at CRO National Cancer Institute (C.R.O.)
  • RaySearch has received an order from Israel-based P-Cure and is deepening its collaboration focusing on advanced proton therapy solutions.
  • CEO Johan Löf and interim CFO Annika Blondeau Henriksson will present RaySearch's interim report for January - September 2023 at a webcast to be held in English on Friday, November 17, 2023 at 10:00-10:30 a.m. CET.

Nature Medicine Publication Highlights Potential for ONWARD® ARC Therapy™ to Improve Mobility After Parkinson’s Disease

Retrieved on: 
Lunedì, Novembre 6, 2023
Euronext, The Michael J. Fox Foundation, Medical research, Swiss Federal Institute of Aquatic Science and Technology, MJFF, Teaching hospital, Clinical research, SCI, Research, INSERM, CHUV, Rehabilitation, Parkinson's disease, EPFL, Spinal cord, Swiss, ARC, Movement, Patient, Pharmaceutical industry, Medical device, Electric light, Nature Medicine

The study participant described in the Nature Medicine publication has been living with Parkinson’s disease for nearly three decades.

Key Points: 
  • The study participant described in the Nature Medicine publication has been living with Parkinson’s disease for nearly three decades.
  • The team collaborated with Dr. Erwan Bezard, a renowned neuroscientist from France’s National Institute of Health and Medical Research (INSERM).
  • Fox Foundation for Parkinson’s Research (MJFF) to implant the ARC-IM System and investigate the effect of ARC Therapy in six additional participants with Parkinson’s disease.
  • This study will assist ONWARD in determining whether to conduct additional clinical trials and potentially commercialize ARC Therapy in the future for those living with Parkinson’s disease.

Aerium Therapeutics Advances Next Generation Antibodies to Protect Immunocompromised Persons Against COVID-19

Retrieved on: 
Mercoledì, Ottobre 4, 2023
COVID-19, Research, Infectious Diseases, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Aerium, Infection, UNC School of Medicine, RBD, Vaccination, Rockefeller University, SARS-CoV-2, Hook effect, Hope, Person, CHUV, Global Health, Death, EPFL, Immunodeficiency, Fred Hutchinson Cancer Research Center, Therapy, Vaccine, ACE2, Lausanne University Hospital, Tropical Islands Resort, Medicine

AER004 was discovered by Michel Nussenzweig at Rockefeller University and also blocks the RBD in a complementary manner to AER003.

Key Points: 
  • AER004 was discovered by Michel Nussenzweig at Rockefeller University and also blocks the RBD in a complementary manner to AER003.
  • Aerium is pursuing a mAb combination strategy to defend against future viral evolution.
  • Aerium is also initiating development of AER005 for potential inclusion in a future product.
  • The mAbs have been modified to provide long-acting protection and exhibit potent and consistent activity against all previous and predominantly circulating variants.

Advancing Cancer Treatment: Leo Cancer Care and THERYQ Collaborate on Innovative FLASHDEEP Patient Positioning

Retrieved on: 
Domenica, Ottobre 1, 2023
CERN, Radiation, Hope, Lausanne University Hospital, European Laboratory for Non-Linear Spectroscopy, CHUV, Organization, FLASH, Patient, Particle physics, Medical imaging, Pharmaceutical industry

This technique has shown promise in targeting cancer cells more effectively while minimizing side effects, making it a potential breakthrough in cancer treatment.

Key Points: 
  • This technique has shown promise in targeting cancer cells more effectively while minimizing side effects, making it a potential breakthrough in cancer treatment.
  • Leo Cancer Care's novel upright patient positioning solution will be integrated into the first unit installed at CHUV.
  • -  Improved Patient Comfort: Innovative upright patient positioning minimizes discomfort during cancer therapy, enhancing patient experience.
  • Both Leo Cancer Care and THERYQ are committed to pushing the boundaries of cancer care, and this collaboration marks a significant milestone in their joint mission to transform the landscape of radiation therapy.

Advancing Cancer Treatment: Leo Cancer Care and THERYQ Collaborate on Innovative FLASHDEEP Patient Positioning

Retrieved on: 
Domenica, Ottobre 1, 2023
CERN, Radiation, Hope, Lausanne University Hospital, European Laboratory for Non-Linear Spectroscopy, CHUV, Organization, FLASH, Patient, Particle physics, Medical imaging, Pharmaceutical industry

This technique has shown promise in targeting cancer cells more effectively while minimizing side effects, making it a potential breakthrough in cancer treatment.

Key Points: 
  • This technique has shown promise in targeting cancer cells more effectively while minimizing side effects, making it a potential breakthrough in cancer treatment.
  • Leo Cancer Care's novel upright patient positioning solution will be integrated into the first unit installed at CHUV.
  • -  Improved Patient Comfort: Innovative upright patient positioning minimizes discomfort during cancer therapy, enhancing patient experience.
  • Both Leo Cancer Care and THERYQ are committed to pushing the boundaries of cancer care, and this collaboration marks a significant milestone in their joint mission to transform the landscape of radiation therapy.

ONWARD® Announces First-in-Human Implant of ARC-IM™ Stimulator with Brain-Computer Interface (BCI) to Restore Arm, Hand, and Finger Function after Spinal Cord Injury

Retrieved on: 
Mercoledì, Settembre 27, 2023
Medical device, European Innovation Council, BCI, Lausanne, Spinal cord, Finger, ARC, Research, Ascending limb of loop of Henle, Movement, CHUV, Trial of the century, Euronext, MD, Artificial intelligence, EPFL, SCI, Safety

The patient also received a wireless brain-computer interface (BCI), designed to initiate thought-driven movement when paired with ARC-IM.

Key Points: 
  • The patient also received a wireless brain-computer interface (BCI), designed to initiate thought-driven movement when paired with ARC-IM.
  • ONWARD ARC-IM delivers targeted, programmed ARC-IM Therapy to the spinal cord to restore movement and other functions after spinal cord injury.
  • ARC-IM Therapy has been applied across multiple clinical feasibility studies to restore mobility and stabilize blood pressure after SCI.
  • For the first time, ARC-IM Therapy has now also been used to restore upper extremity movement and function.